High-throughput Solubility, Permeability, and the MAD PAMPA Mode

Pharmacokinetic Profiling in Drug Research

Volumn , Issue , 2007, Pages 221-241

  Avdeef, Alex ^a  

^a PION INC   (United States)

Author keywords

High throughput solubility; Human intestinal absorption (HIA); MAD PAMPA model; Permeability; Physicochemical strategies; PKa

Indexed keywords

MECHANICAL PERMEABILITY; SOLUBILITY;

HIGH THROUGHPUT; HUMAN INTESTINAL ABSORPTIONS; PHYSICOCHEMICAL STRATEGIES;

THROUGHPUT;

EID: 84956702415     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783906390468.ch14     Document Type: Chapter

References (44)

1. J. B. Dressman, G. L. Amidon, D. Fleisher, J. Pharm. Sci. 1985, 74, 588.
2. G. L. Amidon, H. Lennernäs, V. P. Shah, J. R. Crison, Pharm. Res. 1995, 12, 413.
3. Guidance for Industry,Waiver of in vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System', FDA,Washington D.C., 2000.
4. E. Rinaki, G. Valsami, P. Macheras, Pharm. Res. 2003, 20, 1917.
5. K. Johnson, A. Swindell, Pharm. Res. 1996, 13, 1795.
6. W. Curatolo, Pharm. Sci. Tech. Today 1998, 1, 387.
7. T. F. Weiss, Cellular Biophysics. Vol. I: Transport', The MIT Press, Cambridge, MA, 1996.
8. L. S. Schanker, D. J. Tocco, B. B. Brodie, C. A. M. Hogben, J. Am. Chem. Soc. 1958, 123, 81.
9. M. Kansy, F. Senner, K. Gubernator, J. Med. Chem. 1998, 41, 1007.
10. M. Bermejo, A. Avdeef, A. Ruiz, R. Nalda, J. A. Ruell, O. Tsinman, I. Gonz'lez, C. Fern'ndez, G. S'nchez, T. M. Garrigues, V. Merino, Eur. J. Pharm. Sci. 2004, 21, 429.
11. A.Avdeef, Absorption and Drug Development',Wiley-Interscience,NewYork, 2003, p. 128 -246.
12. Simulations Plus Inc., www.simulations-plus.com.
13. A. Avdeef, Curr. Topics Med. Chem. 2001, 1, 277.
14. K. Balon, B. W. Mueller, B. U. Riebesehl, Pharm. Res. 1999, 16, 882.
15. S. Winiwarter, N. M. Bonham, F. Ax, A. Hallberg, H. Lennernäs, A. Karlen, J. Med. Chem. 1998, 41, 4939.
16. C. A. Lipinski, in Annual Meeting of the Society of Biomolecular Screening, Sept. 24, 2002', Society of Biomolecular Screening, The Hague, The Netherlands, 2002.
17. M. Kansy,H. Fischer, K. Kratzat, F. Senner,B.Wagner, I. Parrilla, in Pharmacokinetic Optimization in Drug Research. Biological, Physicochemical, and Computational Strategies', Eds. B. Testa, H. van deWaterbeemd,G. Folkers,R. Guy,Verlag Helvetica Chimica Acta, Zürich, 2001, p. 447 -464.
18. A. Avdeef, in Pharmacokinetic Optimization in Drug Research. Biological, Physicochemical, and Computational Strategies', Eds. B. Testa, H. van deWaterbeemd, G. Folkers, R. Guy, Verlag Helvetica Chimica Acta, Zürich, 2001, p. 305-326.
19. B. Faller, F. Wohnsland, in Pharmacokinetic Optimization in Drug Research. Biological, Physicochemical, and Computational Strategies', Eds. B. Testa, H. van de Waterbeemd, G. Folkers, R. Guy, Verlag Helvetica Chimica Acta, Zürich, 2001, p. 257 -274.
20. A.Avdeef,M. Strafford, E. Block, M. P. Balogh,W. Chambliss, I. Khan, Eur. J. Pharm. Sci. 2001, 14, 271.
21. F.Wohnsland, B. Faller, J. Med. Chem. 2001, 44, 923.
22. K. Sugano, H. Hamada, M. Machida, H. Ushio, K. Saitoh, K. Terada, Int. J. Pharm. 2001, 228, 181.
23. K. Sugano, H. Hamada, M. Machida, H. Ushio, J. Biomol. Screen. 2001, 6, 189.
24. K. Sugano, N. Takata, M. Machida, K. Saitoh, K. Terada, Int. J. Pharm. 2002, 241, 241.
25. K. Sugano, Y. Nabuchi, M. Machida, Y. Aso, Int. J. Pharm. 2003, 257, 245.
26. C. Zhu, L. Jiang, T. M. Chen, K. K. Hwang, Eur. J. Med. Chem. 2002, 37, 399.
27. D. F. Veber, S. R. Johnson, H. Y. Cheng, B. R. Smith, K. W. Ward, K. D. Kopple, J. Med. Chem. 2002, 45, 2615.
28. L. Di, E. H. Kerns, K. Fan,O. J. McConnell, G. T. Carter, Eur. J. Med. Chem. 2003, 38, 223.
29. E. H. Kerns, J. Pharm. Sci. 2001, 90, 1838.
30. E. H. Kerns, L. Di, Curr. Topics Med. Chem. 2002, 2, 87.
31. L. Di, E. H. Kerns, Curr. Opin. Chem. Biol. 2003, 7, 402.
32. E. H. Kerns, L. Di, Drug Disc. Today 2003, 8, 316.
33. J. A. Ruell, Mod. Drug Disc. 2003, 6, 28.
34. A.Avdeef, in Drug Bioavailability. Estimation of Solubility, Permeability, Absorption and Bioavailability', Eds. H. van deWaterbeemd, H. Lennernäs, P. Artursson,Wiley- VCH,Weinheim, 2003, p. 46-70.
35. K. A. Youdim, A. Avdeef, N. J. Abbott, Drug Disc. Today 2003, 8, 997.
36. P. E. Nielsen, A. Avdeef, Eur. J. Pharm. Sci. 2004, 22, 33.
37. J. A. Ruell, K. L. Tsinman, A. Avdeef, Eur. J. Pharm. Sci. 2003, 20, 393.
38. J. A. Ruell, O. Tsinman, A. Avdeef, Chem. Pharm. Bull. 2004, 52, 561.
39. H. Lennernäs, J. Pharm. Sci. 1998, 87, 403.
40. W. M. Partridge, Peptide Drug Delivery to the Brain', Raven, NewYork, 1991, p. 52- 88.
41. A. Adson, P. S. Burton, T. J. Raub, C. L. Barsuhn, K. L. Audus, N. F. H. Ho, J. Pharm. Sci. 1995, 84, 1197.
42. A. Avdeef, P. Nielsen, O. Tsinman, Eur. J. Pharm. Sci. 2004, 22, 365.
43. H. Liu, C. Sabus, G. T. Carter, C. Du, A. Avdeef, M. Tischler, Pharm. Res. 2003, 20, 1820.
44. S. L. McGovern, E. Caselli,N. Grigorieff, B. K. Shoichet, J. Med. Chem. 2002, 45, 1712.